Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis.

Garami A, Shimansky YP, Rumbus Z, Vizin RCL, Farkas N, Hegyi J, Szakacs Z, Solymar M, Csenkey A, Chiche DA, Kapil R, Kyle DJ, Van Horn WD, Hegyi P, Romanovsky AA.

Pharmacol Ther. 2020 Jan 9:107474. doi: 10.1016/j.pharmthera.2020.107474. [Epub ahead of print] Review.

2.

Fabrication and modelling of fractal, biomimetic, micro and nano-topographical surfaces.

Kyle DJ, Oikonomou A, Hill E, Vijayaraghavan A, Bayat A.

Bioinspir Biomim. 2016 Jul 25;11(4):046009. doi: 10.1088/1748-3190/11/4/046009.

PMID:
27454401
4.
5.

Dibenzazepines and dibenzoxazepines as sodium channel blockers.

Lynch SM, Tafesse L, Carlin K, Ghatak P, Kyle DJ.

Bioorg Med Chem Lett. 2015 Jan 1;25(1):43-7. Epub 2014 Nov 14.

PMID:
25466191
6.

N-Aryl azacycles as novel sodium channel blockers.

Lynch SM, Tafesse L, Carlin K, Ghatak P, Shao B, Abdelhamid H, Kyle DJ.

Bioorg Med Chem Lett. 2015 Jan 1;25(1):48-52. doi: 10.1016/j.bmcl.2014.11.023. Epub 2014 Nov 14.

PMID:
25435147
7.

Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain management.

Tafesse L, Kanemasa T, Kurose N, Yu J, Asaki T, Wu G, Iwamoto Y, Yamaguchi Y, Ni C, Engel J, Tsuno N, Patel A, Zhou X, Shintani T, Brown K, Hasegawa T, Shet M, Iso Y, Kato A, Kyle DJ.

J Med Chem. 2014 Aug 14;57(15):6781-94. doi: 10.1021/jm500818a. Epub 2014 Aug 1.

PMID:
25057800
8.

Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels.

Park JH, Carlin KP, Wu G, Ilyin VI, Musza LL, Blake PR, Kyle DJ.

J Med Chem. 2014 Aug 14;57(15):6623-31. doi: 10.1021/jm500687u. Epub 2014 Jul 24.

PMID:
25026046
9.

Certification of Total Arsenic in Blood and Urine Standard Reference Materials by Radiochemical Neutron Activation Analysis and Inductively Coupled Plasma - Mass Spectrometry.

Paul RL, Davis WC, Yu L, Murphy KE, Guthrie WF, Leber DD, Bryan CE, Vetter TW, Shakirova G, Mitchell G, Kyle DJ, Jarrett JM, Caldwell KL, Jones RL, Eckdahl S, Wermers M, Maras M, Palmer CD, Verostek MF, Geraghty CM, Steuerwald AJ, Parsons PJ.

J Radioanal Nucl Chem. 2014 Mar;299(3):1555-1563.

10.

Identification of molecular phenotypic descriptors of breast capsular contracture formation using informatics analysis of the whole genome transcriptome.

Kyle DJ, Harvey AG, Shih B, Tan KT, Chaudhry IH, Bayat A.

Wound Repair Regen. 2013 Sep-Oct;21(5):762-9. doi: 10.1111/wrr.12077. Epub 2013 Aug 13.

PMID:
23941504
11.

Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.

Cremeans CM, Gruley E, Kyle DJ, Ko MC.

J Pharmacol Exp Ther. 2012 Oct;343(1):72-81. doi: 10.1124/jpet.112.194308. Epub 2012 Jun 28.

12.

Cysteine racemization during the Fmoc solid phase peptide synthesis of the Nav1.7-selective peptide--protoxin II.

Park JH, Carlin KP, Wu G, Ilyin VI, Kyle DJ.

J Pept Sci. 2012 Jul;18(7):442-8. doi: 10.1002/psc.2407. Epub 2012 May 17.

PMID:
22605564
13.

Sodium channel blockers.

Kyle DJ, Ilyin VI.

J Med Chem. 2007 May 31;50(11):2583-8. Epub 2007 May 10. Review. No abstract available.

PMID:
17489575
14.

Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.

Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA.

Arch Neurol. 2006 Nov;63(11):1545-50.

PMID:
17101822
15.

Improving synthetic efficiency using the computational prediction of biological activity.

Broglé KC, Gund T, Kyle DJ.

Comb Chem High Throughput Screen. 2006 Feb;9(2):103-13.

PMID:
16475968
16.

Efficient medicinal chemistry.

Kyle DJ.

Comb Chem High Throughput Screen. 2006 Feb;9(2):77. No abstract available.

PMID:
16475964
17.

Display of somatostatin-related peptides in the complementarity determining regions of an antibody light chain.

Simon PJ, Brogle KC, Wang B, Kyle DJ, Soltis DA.

Arch Biochem Biophys. 2005 Aug 15;440(2):148-57.

PMID:
16051181
18.

8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.

Whitehead JW, Lee GP, Gharagozloo P, Hofer P, Gehrig A, Wintergerst P, Smyth D, McCoull W, Hachicha M, Patel A, Kyle DJ.

J Med Chem. 2005 Feb 24;48(4):1237-43.

PMID:
15715490
19.

Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.

Tafesse L, Sun Q, Schmid L, Valenzano KJ, Rotshteyn Y, Su X, Kyle DJ.

Bioorg Med Chem Lett. 2004 Nov 15;14(22):5513-9.

PMID:
15482915
20.

Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor.

Chen Z, Davies E, Miller WS, Shan S, Valenzano KJ, Kyle DJ.

Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9.

PMID:
15454210
21.

1,3-Dihydro-2,1,3-benzothiadiazol-2,2-diones and 3,4-dihydro-1H-2,1,3-benzothidiazin-2,2-diones as ligands for the NOP receptor.

Goehring RR, Whitehead JF, Brown K, Islam K, Wen X, Zhou X, Chen Z, Valenzano KJ, Miller WS, Shan S, Kyle DJ.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5045-50.

PMID:
15380196
22.

DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.

Valenzano KJ, Miller W, Chen Z, Shan S, Crumley G, Victory SF, Davies E, Huang JC, Allie N, Nolan SJ, Rotshteyn Y, Kyle DJ, Broglé K.

J Pharmacol Exp Ther. 2004 Aug;310(2):783-92. Epub 2004 Mar 30.

PMID:
15054115
23.

An efficient parallel synthesis of capsazepine and capsazepine analogs.

Tafesse L, Kyle DJ.

Comb Chem High Throughput Screen. 2004 Mar;7(2):151-9.

PMID:
15032662
24.

Design and synthesis of novel small molecule N/OFQ receptor antagonists.

Chen Z, Goehring RR, Valenzano KJ, Kyle DJ.

Bioorg Med Chem Lett. 2004 Mar 8;14(5):1347-51.

PMID:
14980696
25.

4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.

Sun Q, Tafesse L, Islam K, Zhou X, Victory SF, Zhang C, Hachicha M, Schmid LA, Patel A, Rotshteyn Y, Valenzano KJ, Kyle DJ.

Bioorg Med Chem Lett. 2003 Oct 20;13(20):3611-6.

PMID:
14505681
26.

Parallel synthesis of a biased library of thiazolidinones as novel sodium channel antagonists.

Sun Q, Tafesse L, Limberis JT, Islam K, Kyle DJ.

Comb Chem High Throughput Screen. 2003 Aug;6(5):481-8. Review.

PMID:
12871054
27.

Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.

Gale DD, Hofer P, Spina D, Seeds EA, Banner KH, Harrison S, Douglas G, Matsumoto T, Page CP, Wong RH, Jordan S, Smith F, Banik N, Halushka PV, Cavalla D, Rotshteyn Y, Kyle DJ, Burch RM, Chasin M.

Pulm Pharmacol Ther. 2003;16(2):97-104. Review.

PMID:
12670778
28.

Human B1 and B2 bradykinin receptors and their agonists target caveolae-related lipid rafts to different degrees in HEK293 cells.

Lamb ME, Zhang C, Shea T, Kyle DJ, Leeb-Lundberg LM.

Biochemistry. 2002 Dec 3;41(48):14340-7.

PMID:
12450400
29.

Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.

Zhang C, Miller W, Valenzano KJ, Kyle DJ.

J Med Chem. 2002 Nov 21;45(24):5280-6.

PMID:
12431054
30.

Variation between sheep in renal excretion of [14C]allantoin.

Prasitkusol P, Ørskov ER, Chen XB, Hovell FD, Kyle DJ.

Br J Nutr. 2002 Jun;87(6):561-8.

PMID:
12067426
31.

Solid-phase and solution-phase parallel synthesis of tetrahydro-isoquinolines via Pictet-Spengler reaction.

Sun Q, Kyle DJ.

Comb Chem High Throughput Screen. 2002 Feb;5(1):75-81.

PMID:
11860342
32.
33.

In vitro genotoxicity testing of ARASCO and DHASCO oils.

Arterburn LM, Boswell KD, Lawlor T, Cifone MA, Murli H, Kyle DJ.

Food Chem Toxicol. 2000 Nov;38(11):971-6.

PMID:
11038233
34.

A developmental safety study in rats using DHA- and ARA-rich single-cell oils.

Arterburn LM, Boswell KD, Henwood SM, Kyle DJ.

Food Chem Toxicol. 2000 Sep;38(9):763-71.

PMID:
10930697
35.

A combined subchronic (90-day) toxicity and neurotoxicity study of a single-cell source of docosahexaenoic acid triglyceride (DHASCO oil).

Arterburn LM, Boswell KD, Koskelo E, Kassner SL, Kelly C, Kyle DJ.

Food Chem Toxicol. 2000 Jan;38(1):35-49.

PMID:
10685012
38.

Oral antinociception and oedema inhibition produced by NPC 18884, a non-peptidic bradykinin B2 receptor antagonist.

de Campos RO, Alves RV, Ferreira J, Kyle DJ, Chakravarty S, Mavunkel BJ, Calixto JB.

Naunyn Schmiedebergs Arch Pharmacol. 1999 Sep;360(3):278-86.

PMID:
10543429
39.

Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia.

Kyle DJ, Schaefer E, Patton G, Beiser A.

Lipids. 1999;34 Suppl:S245. No abstract available.

PMID:
10419166
40.

Oral anti-inflammatory action of NPC 18884, a novel bradykinin B2 receptor antagonist.

Saleh TS, Vianna RM, Creczynski-Pasa TB, Chakravarty S, Mavunkel BJ, Kyle DJ, Calixto JB.

Eur J Pharmacol. 1998 Dec 18;363(2-3):179-87.

PMID:
9881588
41.

Single cell oil sources of docosahexaenoic acid: clinical studies.

Kyle DJ, Arterburn LM.

World Rev Nutr Diet. 1998;83:116-31. Review. No abstract available.

PMID:
9648509
42.

Determination of 15N isotopic enrichment and concentrations of allantoin and uric acid in urine by gas chromatography/mass spectrometry.

Chen XB, Calder AG, Prasitkusol P, Kyle DJ, Jayasuriya MC.

J Mass Spectrom. 1998 Feb;33(2):130-7.

PMID:
9487687
44.

Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.

Austin CE, Faussner A, Robinson HE, Chakravarty S, Kyle DJ, Bathon JM, Proud D.

J Biol Chem. 1997 Apr 25;272(17):11420-5.

45.

Antioedematogenic and antinociceptive actions of NPC 18521, a novel bradykinin B2 receptor antagonist.

De Campos RO, Alves RV, Kyle DJ, Chakravarty S, Mavunkel BJ, Calixto JB.

Eur J Pharmacol. 1996 Dec 5;316(2-3):277-86.

PMID:
8982699
46.

The N terminus of bradykinin when bound to the human bradykinin B2 receptor is adjacent to extracellular Cys20 and Cys277 in the receptor.

Herzig MC, Nash NR, Connolly M, Kyle DJ, Leeb-Lundberg LM.

J Biol Chem. 1996 Nov 22;271(47):29746-51.

47.

Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system.

Mavunkel BJ, Lu Z, Goehring RR, Lu S, Chakravarty S, Perumattam J, Novotny EA, Connolly M, Valentine H, Kyle DJ.

J Med Chem. 1996 Aug 2;39(16):3169-73.

PMID:
8759638
48.

Preclinical evaluation of single-cell oils that are highly enriched with arachidonic acid and docosahexaenoic acid.

Boswell K, Koskelo EK, Carl L, Glaza S, Hensen DJ, Williams KD, Kyle DJ.

Food Chem Toxicol. 1996 Jul;34(7):585-93.

PMID:
8761351
49.

Novel bradykinin receptor antagonists from a structurally directed non-peptide combinatorial library.

Chakravarty S, Mavunkel BJ, Goehring RR, Kyle DJ.

Immunopharmacology. 1996 Jun;33(1-3):61-7. No abstract available.

PMID:
8856116
50.

Computational screening of combinatorial libraries.

Zheng Q, Kyle DJ.

Bioorg Med Chem. 1996 May;4(5):631-8.

PMID:
8804526

Supplemental Content

Support Center